CD8A and acute myeloid leukemia: Since DNMT3A-R882 and NPM1 mutations often co-occur (11), it is worth exploring whether combined transfer of CD8 T cells with the NPM1-specific TCR and CD4 T cells with the DNMT3A-specific TCR leads to more effective eradication of AML with DNMT3A and NPM1 co-mutations as compared to NPM1-specific CD8 T cells alone.